{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Galano-Frutos JJ"],"funding":["Gobierno de Aragon","JPIAMR","Ministerio de Ciencia e Innovación","MICINN"],"pagination":["e27982"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11059415"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(7)"],"pubmed_abstract":["<h4>Objectives</h4>The rise of antibiotic-resistant <i>Streptococcus pneumoniae</i> (<i>Sp</i>) poses a significant global health threat, urging the quest for novel antimicrobial solutions. We have discovered that the human hormone l-thyroxine has antibacterial properties. In order to explore its drugability we perform here the characterization of a series of l-thyroxine analogues and describe the structural determinants influencing their antibacterial efficacy.<h4>Method</h4>We performed a high-throughput screening of a library of compounds approved for use in humans, complemented with ITC assays on purified <i>Sp</i>-flavodoxin, to pinpoint molecules binding to this protein. Antimicrobial <i>in vitro</i> susceptibility assays of the hit compound (l-thyroxine) as well as of 13 l-thyroxine"],"journal":["Heliyon"],"pubmed_title":["L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria."],"pmcid":["PMC11059415"],"funding_grant_id":["PID2022-141068NB-I00","PID2019-107293 GB-I00","E45_23R"],"pubmed_authors":["Schaible UE","Iguarbe V","Mamat U","Ainsa JA","Sancho J","Maity R","Galano-Frutos JJ","Velazquez-Campoy A"],"additional_accession":[]},"is_claimable":false,"name":"L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria.","description":"<h4>Objectives</h4>The rise of antibiotic-resistant <i>Streptococcus pneumoniae</i> (<i>Sp</i>) poses a significant global health threat, urging the quest for novel antimicrobial solutions. We have discovered that the human hormone l-thyroxine has antibacterial properties. In order to explore its drugability we perform here the characterization of a series of l-thyroxine analogues and describe the structural determinants influencing their antibacterial efficacy.<h4>Method</h4>We performed a high-throughput screening of a library of compounds approved for use in humans, complemented with ITC assays on purified <i>Sp</i>-flavodoxin, to pinpoint molecules binding to this protein. Antimicrobial <i>in vitro</i> susceptibility assays of the hit compound (l-thyroxine) as well as of 13 l-thyroxine","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T11:31:27.607Z","creation":"2026-04-08T11:52:48.237Z"},"accession":"S-EPMC11059415","cross_references":{"pubmed":["38689973"],"doi":["10.1016/j.heliyon.2024.e27982"]}}